CD27–CD70 Interaction: Unravelling its Implication in Normal and Neoplastic B-Cell Growth

References

• Tartaglia L. A., Weber R. F., Figari I. S., Reynolds C., Palladino M. A., Goeddel D. V. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. USA 1991; 88: 9292
   PubMed Web of Science ®Google Scholar
• Ware C. F., Crowe P. D., Grayson M. H., Androlewicz M. J., Browning J. L. Expression of surface lymphotoxin and tumor necrosis factor on activated T.B, and natural killer cells. J. Immunol 1992; 149: 3881
   PubMed Web of Science ®Google Scholar
• Crowe P. D., Vanarsdale T. L., Walter B. N., Ware C. F., Hession C., Ehrenfels B., Browning J. L., Din W. S., Goodwin R. G., Smith C. A. A Lymphotoxin-β-Specific Receptor. Science 1994; 264: 707
   PubMed Web of Science ®Google Scholar
• Browning J. L., Ngam-Ek A., Lawton P., DeMarinis J., Tizard R., Pingchang Chow E., Hession C., O'Brine-Greco B., Foley S. F., Ware C. F. Lymphotoxin β, a novel member of the TNF family that forms a heterodimeric complex with lymphotoxin on the cell surface. Cell 1993; 72: 847
   PubMed Web of Science ®Google Scholar
• De Togni P., Goellner J., Ruddle N. H., Streeter P. R., Fick A., Mariathasan S., Smith S. C., Carlson R., Shornick L. P., Strauss-Schoenberger J., Russell J. H., Kerr R., Chaplin D. D. Abnormal Development of Peripheral Lymphoid Organs in Mice Deficient in Lymphotoxin. Science 1994; 264: 703
   PubMed Web of Science ®Google Scholar
• Watanabe-Fukunaga R., Brannan C. I., Copeland N. G., Jenkins N. A., Nagata S. Lymphoproliferation disorder in mice explained by defects in FAS antigen that mediates apoptosis. Nature 1992; 356: 314
   PubMed Web of Science ®Google Scholar
• Takahashi T., Tanaka M., Brannan C. I., Jenkins N. A., Copeland N. G., Suda T., Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969
   PubMed Web of Science ®Google Scholar
• Camerini D., Walz G., Loenen W. A. M., Borst J., Seed B. The T cell activation antigen CD27 is a member of the Nerve Growth Factor/Tumor Necrosis Factor receptor gene family. J. Immunol 1991; 147: 3165
   PubMed Web of Science ®Google Scholar
• Hintzen R. Q., de Jong R., Lens S. M. A., Brouwer M., Baars P., van Lier R. A. W. Regulation of CD27 expression on subsets of mature T-lymphocytes. J. Immunol 1993; 151: 2426
   PubMed Web of Science ®Google Scholar
• Hintzen R. Q., Lens S. M., Beckmann M. P., Lynch D., Goodwin R. G., van Lier R. A. W. Characterization of the human CD27 ligand, a novel member of the TNF gene family. J. Immunol 1994; 152: 1762
   PubMed Web of Science ®Google Scholar
• Hintzen R. Q., Lens S. M. A., Koopman G., Pals S. T., Spits H., van Lier R. A. W. CD70 represents the human ligand for CD27. Int. Immunol 1994; 6: 477
   PubMed Web of Science ®Google Scholar
• Dürkop H., Latza U., Hummel M., Eitelbach F., Seed B., Stein H. Molecular cloning and expression of a new member of the nerve growth factor family that is characteristic for Hodgkin's Disease. Cell 1992; 68: 421
   PubMed Web of Science ®Google Scholar
• Smith C. A., Gruss H. J., Davis T., Anderson D., Farrah T., Baker E., Sutherland G. R., Brannan C. I., Copeland N. G., Jenkins N. A., Grabstein K. H., Gliniak B., McAlister I. B., Fanslow W., Alderson M., Falk B., Gimpel S., Din W. S., Gillis S., Goodwin R. G., Armitage R. J. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging superfamily of cytokines with homology to TNF. Cell 1993; 73: 1349
   PubMed Web of Science ®Google Scholar
• Stamenkovic I., Clark E. A., Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO 1989; 8: 1403
   PubMed Web of Science ®Google Scholar
• Armitage R. J., Fanslow W. C., Strockbine L., Sato T. A., Clifford K. N., Macduff B. M., Anderson D. M., Gimpel S. D., Davis-Smith T., Maliszewski C. R., Clark E. A., Smith C. A., Grabstein K. H., Cosman D., Spriggs M. K. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357: 80
   PubMed Web of Science ®Google Scholar
• Pollok K. E., Kim Y. -J., Zhou Z., Hurtado J., Kim K. K., Pickard R. T., Kwon B. S. Inducible T cell antigen 4-1BB: Analysis of expression and function. J. Immunol 1993; 150: 771
   PubMed Web of Science ®Google Scholar
• Pollok K. E., Kim Y.-J., Hurtado J., Kim K. K., Kwon B. S. 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-μ-primed splenic B cells. Eur. J. Immunol 1994; 24: 367
   PubMed Web of Science ®Google Scholar
• Goodwin R. G., Din W. S., Davis-Smith T., Anderson D. M., Sato T. A., Maliszewski C. R., Brannan C. I., Copeland N. G., Jenkins N. A., Farrah T., Armitage R. J., Fanslow W. C., Smith C. A. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur. J. Immunol 1993; 23: 2631
   PubMed Web of Science ®Google Scholar
• Mallet S., Fossum S., Barclay A. N. Characterisation of the MRC OX40 antigen of activated CD4 positive lymphocytes-a molecule related to nerve growth factor receptor. EMBO 1990; 9: 1063
   PubMed Web of Science ®Google Scholar
• Calderhead D. M., Buhlmann J. E., van den Eertwegh A. J. M., Claasen E., Noelle R. J., Perry Fell H. Cloning of mouse OX40: a T cell activation marker that may mediate T-B cell interactions. J. Immunol 1993; 151: 5261
   PubMedGoogle Scholar
• Smith C. A., Farrah T., Goodwin R. G. The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death. Cell 1994; 76: 959
   PubMed Web of Science ®Google Scholar
• Smith C., Davis T., Wighall J., Din W., Farrah T., Upton C., McFadden G., Goodwin R. G. T2 open reading frame from Shope Fibroma Virus encodes a soluble form of the TNF receptor. Biochem. Biophys. Res. Commun 1991; 176: 335
   PubMed Web of Science ®Google Scholar
• Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the FAS ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169
   PubMed Web of Science ®Google Scholar
• Goodwin R. G., Alderson M. R., Smith C. A., Armitage R. J., Vandenbos T., Jerzy R., Tough T. W., Schoenborn M., Davis-Smith T., Hennen K., Falk B., Cosman D., Baker E., Sutherland G. R., Grabstein K. H., Farrah T., Giri J. G., Beckmann M. P. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to Tumor Necrosis Factor. Cell 1993; 73: 447
   PubMed Web of Science ®Google Scholar
• Gray P. W., Aggarwal B. B., Benton C. W., Bringman T. S., Henzel W. J., Jarret J. A., Leung D. W., Moffat B., Svedersky L. P., Palladini M. A., Nedwin G. E. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumor necrosis activity. Nature 1984; 312: 721
   PubMed Web of Science ®Google Scholar
• Trauth B. C., Klas C., Peters A. M. J., Matzku S., Möller, Falk W., Debatin K. M., Krammer P. H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301
   PubMed Web of Science ®Google Scholar
• Rousset F., Garcia E., Banchereau J. Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen. J. Exp. Med 1991; 173: 705
   PubMed Web of Science ®Google Scholar
• Banchereau J., Rousset F. Growing human B lymphocytes in the CD40 system. Nature 1991; 353: 678
   PubMed Web of Science ®Google Scholar
• van Lier R. A. W., Borst J., Vroom Th. M., Klein H., van Mourik P., Zeijlemaker W. P., Melief C. J. M. Tissue distribution and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J. Immunol 1987; 139: 1589
   PubMed Web of Science ®Google Scholar
• Umeda T., Hara T., Niijima T. Cytotoxic effect of tumor necrosis factor on human lymphocytes and specific binding of the factor to the target cells. Cell. Mol. Biol 1983; 29: 349
   PubMed Web of Science ®Google Scholar
• Kashiwa H., Wright S. C., Bonavida B. Regulation of B cell maturation and differentiation. I. Suppression of pokeweed mitogen-induced B cell differentiation by tumor necrosis factor (TNF). J. Immunol 1987; 138: 1383
   PubMed Web of Science ®Google Scholar
• Pfeffer K., Matsuyama T., Kündig T. M., Wakeham A., Kishihara K., Shahinian A., Wiegmann K., Ohashi P. S., Kröonke M., Mak T. W. Mice deficient for the 55 kd Tumor Necrosis Factor Receptor are resistant to endotoxic shock, yet succomb to L. monocytogenes infection. Cell 1993; 73: 457
   PubMed Web of Science ®Google Scholar
• Rothe J., Lesslauer W., Lötscher H., Lang Y., Koebel P., Köntgen F., Althage A., Zinkemagel R., Steinmetz M., Bluethmann H. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenesis. Nature 1993; 364: 798
   PubMed Web of Science ®Google Scholar
• Cohen P. L., Eisenberg R. A. Lpr and gld: Single gene models of systemic autóimmunity and lymphoproliferative disease. Annu. Rev. Immunol 1991; 9: 243
   PubMed Web of Science ®Google Scholar
• Aruffo A., Farrington M., Hollenbaugh D., Li X., Milatovich A., Nonoyama S., Bajorath J., Grosmaire L. S., Stenkamp R., Neubauer M., Roberts R. L., Noelle R. J., Ledbetter J. A., Francke U., Ochs H. D. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993; 72: 291
   PubMed Web of Science ®Google Scholar
• Korthäuer U., Graf D., Mages H. W., Brière F., Padayachee M., Malcolm S., Ugazio A. G., Notarangelo L. D., Levinsky R. J., Kroczek R. A. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993; 361: 539
   PubMed Web of Science ®Google Scholar
• Allen R. C., Armitage R. J., Conley M. E., Rosenblatt H., Jenkins N. A., Copeland N. G., Bedell M. A., Edelhoff S., Disteche C. M., Simoneaux D. K., Fanslow W. C., Belmont J., Spriggs M. K. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993; 259: 990
   PubMed Web of Science ®Google Scholar
• Borst J., Sluyser C., de Vries E., Klein H., Melief C. J. M., van Lier R. A. W. Alternative molecular form of human T cell specific antigen CD27 expressed upon T cell activation. Eur. J. Immunol 1989; 19: 357
   PubMed Web of Science ®Google Scholar
• Maurer D., Holter W., Majdic O., Fischer G. F., Knapp W. CD27 expression by a distinct subpopulation of human B lymphocytes. Eur. J. Immunol 1990; 20: 2679
   PubMed Web of Science ®Google Scholar
• Sugita K., Robertson M. J., Torimoto Y., Ritz J., Schlossman S. F., Morimoto C. Participation of the CD27 antigen in the regulation of IL-2-activated human natural killer cells. J. Immunol 1992; 149: 1199
   PubMed Web of Science ®Google Scholar
• Martorell J., Rojo I., Vilella R., Martinez-Carceres E., Vives J. CD27 induction on thymocytes. J. Immunol 1990; 145: 1356
   PubMed Web of Science ®Google Scholar
• de Jong R., Brouwer M., Hooibrink B., van der Pouw-Kraan T., Miedema F., van Lier R. A. W. The CD27-subset of peripheral blood memory CD4+ lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo. Eur. J. Immunol 1992; 22: 993
   PubMed Web of Science ®Google Scholar
• Hintzen R. Q., de Jong R., Hack C. E., Chamuleau M., De Vries F. R., ten Berge I. J. M., Borst J., van Lier R. A. W. A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex. J. Immunol 1991; 147: 29
   PubMed Web of Science ®Google Scholar
• Loenen W. A. M., de Vries E., Gravestein L. A., Hintzen R. Q., van Lier R. A. W., Borst J. The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis. Eur. J. Immunol 1992; 22: 447
   PubMed Web of Science ®Google Scholar
• Hintzen R. Q., van Lier R. A. W., Kuijpers K. C., Baars P. A., Schaasberg W., Lucas C. J., Polman C. H. Elevated levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol 1991; 35: 211
   PubMed Web of Science ®Google Scholar
• De Rie M. A., Hamerlinck F., Hintzen R. Q., Bos J. D., van Lier R. A. W. Quantification of soluble CD27, a T-cell activation antigen, and soluble interleukin-2 receptor in serum from patients with psoriasis. Arch. Dermatol. Res 1991; 283: 533
   PubMed Web of Science ®Google Scholar
• Yazdanbakhsh M., Sartono E., Kruize Y. C. M., Kurniawan A., van der Pouw-Kraan T., Van der Meide P. H., Selkirk M. E., Partono F., Hintzen R. Q., van Lier R. A. W., Maizels R. M. Elevated levels of T cell activation antigen CD27 and increased interleukin-4 production in human lymphatic filariasis. Eur. J. Immunol 1993; 23: 3312
   PubMed Web of Science ®Google Scholar
• van Oers M. H. J., Pals S. T., Evers L., Van der Schoot C. E., Koopman G., Bonfrer J. M. G., Hintzen R. Q., Von dem Kr., Borne A. E. G., van Lier R. A. W. Expression and release of CD27 in human malignancies. Blood 1993; 82: 340
   Google Scholar
• Sugita K., Torimoto Y., Nojima Y., Daley J. F., Schlossman S. F., Morimoto C. The 1A4 molecule (CD27) is involved in T cell activation. J. Immunol 1991; 147: 1477
   PubMed Web of Science ®Google Scholar
• Bigler R. D., Bushkin Y., Chiorazzi N. S152 (CD27). A modulating disulfide-linked T cell activation antigen. J. Immunol 1988; 141: 21
   PubMed Web of Science ®Google Scholar
• Bowman M. R., Crimmins M. A. V., Yetz-Aldape J., Kriz R., Kelleher K., Herrmann S. The cloning of CD70 and its identification as the ligand for CD27. J. Immunol 1994; 152: 1756
   PubMed Web of Science ®Google Scholar
• Hintzen R. Q., Lens S. M. A., Lammers K., Kuiper H., Beckmann M. P., Goodwin R. G., van Lier R. A. W. Engagement of CD27 with its ligand (CD70) provides a second signal for T-cell activation. 1994, Submitted for publication
   Google Scholar
• Hintzen R. Q., de Jong R., Lens S. M. A., van Lier R. A. W. CD27: marker and mediator of T-cell activation. Imm. Today 1994; 15: 307
   PubMedGoogle Scholar
• Maurer D., Fischer G. F., Fae I., Majdic O., Stuhlmeier K., Von Jeney N., Holter W., Knapp W. IgM and IgG but not cytokine secretion is restricted to the CD27+ B lymphocyte subset. J. Immunol 1992; 148: 3700
   PubMed Web of Science ®Google Scholar
• Yewdell J. W., Bennink J. R. Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv. Immunol 1992; 52: 1
   PubMed Web of Science ®Google Scholar
• Trentin L., Zambello R., Agostini C., Siviero F., Adami F., Marcolongo R., Raimondi R., Chisesi T., Pizzolo G., Semenzato G. Expression and functional role of tumor necrosis factor receptors on leukemic cells from patients with type B chronic lymphoproliferative disorders. Blood 1993; 81: 752
   PubMed Web of Science ®Google Scholar
• Ryffel B., Brockhaus M., Dürmüller U., Gudat F. Tumor necrosis factor receptors in lymphoid tissues and lymphomas. Am. J. Pathol 1991; 139: 7
   PubMed Web of Science ®Google Scholar
• Digel W., Schöniger W., Stefanic M., Janssen H., Buck C., Schmid M., Raghavachar A., Porzsolt F. Receptors for tumor necrosis factor on neoplastic B cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo. Blood 1990; 76: 1607
   PubMed Web of Science ®Google Scholar
• Van Kooten C., Rensink I., Aarden L., Van Oers R. Interleukin-4 inhibits both paracrine and autocrine Tumor Necrosis Factor-α-induced proliferation of B Chronic Lymphocytic Leukemia cells. Blood 1992; 80: 1299
   PubMed Web of Science ®Google Scholar
• Nerl C., Janssen O., Kabelitz D. B cell maturation in chronic lymphocytic leukemia. III. Effect of recombinant cytokines on leukemic B cell proliferation. Leukemia 1988; 2: 505
   Google Scholar
• Cordingly F. T., Hoffbrand A. V., Heslop H. E., Turner M., Bianchi A., Reitti J. E., Vyakamam A., Meager A., Brenne M. K. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet 1988; ii: 969
   Google Scholar
• Digel W., Stefanic M., Schröoniger W., Buck C., Raghavachar A., Frichofen N., Heimpel H., Porzsolt F. Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood 1989; 73: 1242
   PubMed Web of Science ®Google Scholar
• Foa R., Massaia M., Cardona S., Tos A. G., Bianchi A., Attisano C., Guarini A., Di Celle P. F., Fierre M. T. Production of tumor necrosis factor-α by B-cell chronic lymphocytic leukemia cells: a possible role of TNF in the progression of the disease. Blood 1990; 76: 393
   PubMed Web of Science ®Google Scholar
• Moberts R., Hoogerbrugge H., Van Agthoven T., Löwenberg B., Touw I. Proliferative response of highly purified B chronic lymphocytic leukemia cells in serum free culture to interleukin-2 and tumour necrosis factors alpha and beta. Leukemia Research 1989; 13: 973
   PubMed Web of Science ®Google Scholar
• Heslop H. E., Bianchi A. C. M., Cordingley F. T., Turner M., Chandima W., De Mel P., Hoffbrand A. V., Brenner M. K. Effects of interferon α on autocrine growth factor loops in B lymphoproliferative disorders. J. Exp. Med 1990; 172: 1729
   PubMed Web of Science ®Google Scholar
• Buck C., Digel W., Schöniger W., Stefanic M., Raghavachar A., Heimpel H. F., Porzsolt F. Tumor necrosis factor-α, but not lymphotoxin, stimulates growth of tumor cells in hairy cell leukemia. Leukemia 1990; 41: 431
   Google Scholar
• Barut B. A., Cochran M. K., O'Hara C., Anderson K. C. Response patterns of Hairy Cell Leukemia to B cell mitogens and growth factors. Blood 1990; 76: 2091
   PubMed Web of Science ®Google Scholar
• Leithauser F., Dhein J., Mechtersheimer G., Koretz K., Bruderlein S., Henne C., Schmidt A., Debatin K.-M., Krammer P. H., Möller P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest 1993; 69: 415
   PubMed Web of Science ®Google Scholar
• Ellis T. M., Simms P. E., Slivnick D. J., Jäck H. -M., Fisher R. I. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J. Immunol 1993; 151: 2380
   PubMed Web of Science ®Google Scholar
• Schwab U., Stein H., Gerdes J., Lemke H., Kirchner H. H., Schaadt M. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's Disease and a subset of normal lymphoid cells. Nature 1982; 299: 65
   PubMed Web of Science ®Google Scholar
• Schwarting R., Stein H. Cluster report: CD30. Leucocyte Typing IV, W. Knapp. Oxford University Press. 1989; 419
   Google Scholar
• Pizzolo G., Vinante F., Chilosi M., Dallenbach F., Josimovic-Alasevic O., Diamantstein T., Stein H. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. Br. J. Haematol 1990; 75: 282
   PubMed Web of Science ®Google Scholar
• Beiske K., Clark E. A., Holte H., Ledbetter J. A., Smeland E. B., Godal T. Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphological subsets. Int. J. Cancer 1988; 42: 521
   PubMed Web of Science ®Google Scholar
• Fluckiger A. C., Rossi J. F., Bussel A., Bryon P., Banchereau J., Defrance T. Responsiveness of Chronic Lymphocytic Leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 1992; 80: 3173
   PubMed Web of Science ®Google Scholar
• Funakoshi S., Longo D. L., Beckwith M., Conley D. K., Tsarfaty G., Tsarfaty I., Armitage R. J., Fanslow W. C., Spriggs M. K., Murphy W. J. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994; 83: 2787
   PubMed Web of Science ®Google Scholar
• Latza U., Dürkop H., Schnitter S., Ringeling J., Eitelbach F., Hummel M., Fonatsch C., Stein H. The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen. Eur. J. Immunol 1994; 24: 677
   PubMed Web of Science ®Google Scholar
• Stein H., Schwarting R., Niedobitek G., Dallenbach F. Cluster report: CDw70. Leucocyte Typing IV, W. Knapp. Oxford University Press, Oxford 1989; 446
   Google Scholar
• van den Eertwegh A. J. M., Noelle R. J., Roy M., Shepherd D. M., Aruffo A., Ledbetter J. A., Boersma W. J. A., Claassen E. In Vivo CD40-gp39 Interactions Are Essential for Thymus-dependent Humoral Immunity. I Vivo Expression of CD40 Ligand, Cytokines, and Antibody Production Delineates Sites of Cognate T-B cell Interactions. J. Exp. Med 1993; 178: 1555
   PubMed Web of Science ®Google Scholar